Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIFN alfa-2b for Relapse Reduction in CHB (CEASE2.0)
NCT06900166Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (3 arms), sponsored by Huashan Hospital. Primary endpoint: Number of participants who relapse. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06900166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900166.